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ABSTRACT
Background
As a result of rising levels of drug resistance to conventional monotherapy, the World Health
Organization (WHO) and other international organisations have recommended that malaria
endemic countries move to combination therapy, ideally with artemisinin-based combinations
(ACTs). Cost is a major barrier to deployment. There is little evidence from field trials on the
cost-effectiveness of these new combinations.
Methods and Findings
An economic evaluation of drug combinations was designed around a randomised
effectiveness trial of combinations recommended by the WHO, used to treat Tanzanian
children with non-severe slide-proven malaria. Drug combinations were: amodiaquine (AQ), AQ
with sulfadoxine-pyrimethamine (AQþSP), AQ with artesunate (AQþAS), and artemether-
lumefantrine (AL) in a six-dose regimen. Effectiveness was measured in terms of resource
savings and cases of malaria averted (based on parasitological failure rates at days 14 and 28).
All costs to providers and to patients and their families were estimated and uncertain variables
were subjected to univariate sensitivity analysis. Incremental analysis comparing each
combination to monotherapy (AQ) revealed that from a societal perspective AL was most
cost-effective at day 14. At day 28 the difference between AL and AQþAS was negligible; both
resulted in a gross savings of approximately US$1.70 or a net saving of US$22.40 per case
averted. Varying the accuracy of diagnosis and the subsistence wage rate used to value unpaid
work had a significant effect on the number of cases averted and on programme costs,
respectively, but this did not change the finding that AL and AQþAS dominate monotherapy.
Conclusions
In an area of high drug resistance, there is evidence that AL and AQþAS are the most cost-
effective drugs despite being the most expensive, because they are significantly more effective
than other options and therefore reduce the need for further treatment. This is not necessarily
the case in parts of Africa where recrudescence following SP and AQ treatment (and their
combination) is lower so that the relative advantage of ACTs is smaller, or where diagnostic
services are not accurate and as a result much of the drug goes to those who do not have
malaria.
The Editors’ Summary of this article follows the references.
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Rising drug resistance levels to conventional monotherapy
has resulted in strong arguments for a move to combination
treatment for all malaria in Africa, especially artemisinin-
based combination therapies (ACTs) [1–2]. The relatively high
cost of these new medicines compared to current mono-
therapy represents a major barrier to their effective
implementation [3–6]. Currently most people pay for their
own malaria treatment, but whilst in areas where mono-
therapy is failing they are prepared to pay more for
combination therapy than for monotherapy, they are not
prepared to pay the current market cost of ACTs [6]. This
means that subsidising these drugs is likely to be the only
realistic option if they are to reach those who need them
most, and especially if they are to reach the poorest [7]. In
Africa, where there are many urgent competing priorities,
this policy is unlikely to be either sustainable or politically
realistic unless it is cost-effective. Theoretical projections of
the cost-effectiveness at a societal level have suggested that it
is likely to be a reasonably cost-effective approach compared
to other public health interventions [8].
Studies have not examined the cost-effectiveness of these
drugs in areas of Africa with failing monotherapy in using
original data, and in particular we are not aware of any that
have compared the current treatment options available to
public health and clinical decision-makers in Africa. These
are essential data for rational policy-making if public funds
(e.g., a subsidy) are likely to be involved. We therefore set out
to compare the cost-effectiveness of the three currently
available drug combinations to treat children with non-
severe, slide-proven malaria compared to monotherapy
(amodiaquine [AQ]). The combinations were AQ with
sulfadoxine-pyrimethamine (AQþSP), AQ with artesunate
(AQþAS) or artemether-lumefantrine ([AL], six-dose regi-
men). The study was undertaken in the context of a clinical
trial where the effectiveness of the drugs taken unsupervised
was measured directly [9]. In this study we compare the costs,
health effects, and cost-effectiveness of each treatment.
Methods
The study was conducted at Teule Hospital, a designated
district hospital located in Muheza, a small town in the
northeast district of Tanga, Tanzania with an EIR (entomo-
logical inoculation rate) of over 300 and where the average
individual has around three clinical attacks of malaria a year
[10]. There are high levels of drug resistance to both SP and
amodiaquine monotherapy [9,11,12]. The clinical effective-
ness of drugs and combinations was determined by way of a
trial conducted between September 2002 and October 2004,
reported elsewhere [9]. In brief, 1,811 children were
randomised to one of the four treatment arms. By day 28,
the parasitological failure rates were 76% for AQ mono-
therapy, 61% for AQþSP, 40% for AQþAS, and 21% for AL.
An incremental approach was used to estimate costs and
effects. This involved comparing each of the new combina-
tion medicines against the existing monotherapy of AQ. SP is
currently ﬁrst-line and AQ second-line treatment for
uncomplicated malaria in Tanzania. Pilot testing for this
trial revealed unacceptably high levels of resistance to SP, so
AQ was selected as the monotherapy against which each
combination medicine was compared. Economic costs were
estimated using the bottom-up approach in which all
resources required in the delivery of treatment are valued
[13]. Health effects were measured in terms of cases of
malaria averted (based on parasitological failure rates at days
14 and 28); details of the methodology of the effectiveness
trial are published [9].
Findings are presented from both a provider (hospital) and
a societal perspective. For the provider perspective, only
those costs and effects borne by the provider are considered;
this is the cost-effectiveness from the point of view of a
ministry of health. For the societal perspective, the costs and
effects borne by patients and their families are combined
with those of the provider, which is especially relevant when
considering the case for subsidy.
The main areas of resource use for the health service were
medication, personnel, rent for hospital space, and use of a
microscope. Published market drug prices were used [14–16],
and where a child’s dose was not speciﬁed, it was assumed to
be 50% of an adult dose. Staff salaries and building costs were
prorated based on the number of malaria patients under the
age of 5. The microscope was annualised over an estimated
useful life of two years at a discount rate of 3% [17].
Families of patients incurred both indirect and direct costs.
Direct costs included out-of-pocket expenses such as hospital
fees, transport, and medication, as well as miscellaneous
expenditures such as informal payments made to medical
staff, food, and blankets. Hospital fees were not charged for
children under the age of 5, but fees were rendered if the
registration card needed to be replaced. Medical costs
included extra antibiotics or blood transfusions. Indirect
costs included time lost as a result of caring for a sick child at
home, travelling to hospital, and waiting at hospital for
treatment. Time lost was valued at the prevailing minimum
subsistence wage rate in Tanzania (i.e., 30,000 Tanzanian
shillings in 2004).
Estimation of resources savings were based on the cost of
current ﬁrst-line treatment with SP. Current therapy differed
from the intervention treatments in two key respects: type of
medicine used and the time families spent seeking treatment.
Current treatment with SP was valued using the hospital’s
procurement prices at the dispensary. Indirect costs were
measured for patients taking the current treatment. These
costs were the same as for AQ, as parasitological failure rates
and drug cost are almost exactly the same as for SP in this
setting [9]. For the remaining combination treatments,
indirect costs were assumed to be lower due to increased
levels of effectiveness. Rates of relative effectiveness for each
of the combinations have been applied to the indirect costs of
current treatment.
Costs incurred at the household level were collected
through structured interviews at the hospital outpatient
facility. Sixty-three parents of febrile children under the age
of 5 diagnosed with malaria were selected between March and
April 2005. Parents were purposively selected from different
ethnic, socioeconomic, and rural/urban locations. All partic-
ipants gave informed consent. All remaining costs were
collected from the principle investigators of the trial and
from hospital accounting records. Staff salaries were ob-
tained from the standard payroll scales for Tanzania. All costs
were converted from Tanzanian shillings to US dollars based
on the exchange rate prevailing at the outset of the trial (i.e.,
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their present value [18]. Research costs were excluded from
the analysis. Uncertain variables (where variation in the
assumptions might affect cost-effectiveness) were subjected to
a univariate sensitivity analysis including accuracy of diag-
nosis, drug prices, the discount rate, and subsistence wage.
The study was given clearance by the ethics committees if the
National Institute for Medical Research, Tanzania and the
London School of Hygiene & Tropical Medicine.
Results
The programme costs for each treatment are shown in
Table 1. For the provider, the higher unit price of AL meant
that the cost of implementing this treatment was higher than
for the others. For patients and their families, current
treatment with SP and treatment with AQ were the most
costly, due to the need for retreatment. The indirect costs to
patients and their families were the largest component of
programme costs for all treatments.
Cost-effectiveness data are shown in Table 2. By day 14, AL
was revealed to be the most effective treatment with 495 cases
averted. By day 28 the effectiveness of all treatments had
fallen but AL remained most effective, averting 382 cases of
malaria. Comparing cost-effectiveness ratios for the three
combination treatments against monotherapy (AQ) revealed
that from a societal perspective AL was most cost-effective at
day 14; resulting in a gross saving of US$1.51 or a net saving
of US$22.24 per case averted. At day 28 the difference
between the two most cost-effective treatments of AL and
AQþAS was negligible; both resulted in gross savings of
approximately US$1.70 or a net saving of US$22.40 per case
averted. From a provider perspective, AL was most costef-
fective at days 14 and 28.
The greatest resource savings were associated with AL.
From a societal perspective, total savings were US$10,261 at
day 14 and US$7,919 at day 28. The equivalent ﬁgures from a
provider perspective are US$2,520 at day 14 and US$1,944 at
day 28. For all treatments, savings were higher at day 14
compared with day 28. The greatest reduction in savings to
society between days 14 and 28 was reported for AQ (61%).
Comparing the three combination treatments against mono-
therapy (AQ) showed that from a societal perspective AL was
again most-cost-effective at day 14. By day 28 there was only a
minor difference between AL and AQþAS.
The results of the sensitivity analysis are shown in Table 3.
The effectiveness of all treatments was strongly inﬂuenced by
accuracy of diagnosis. For example, assuming that 70% of all
patients treated for malaria do not in fact have malaria, the
number of incremental cases averted using AL falls from 325
to 98 at day 28 while programme costs remain the same. Each
combination treatment is compared to monotherapy, which
is also assumed to experience a 70% reduction in accuracy of
diagnosis. So while cost-effectiveness falls, combinations such
as AL remain better value for money relative to monotherapy
by saving more resources and averting more cases of malaria.
Changing the subsistence wage rate also led to notable
changes in costs, but this, again, did not change the fact that
combination treatments such as AL continued to be more
cost-effective than monotherapy. Altering drug prices or the
discount rate had little effect on the ﬁndings of this study.
Table 1. Programme Costs
Perspective Cost
Category
Item Mean Discounted Cost per Patient (US$)
Current
Recommended
First-Line
Treatment (SP)
Amodiaquine Amodiaquine
þ Sulfadoxine-
Pyrimethamine
Amodiaquine
þ Artesunate
Artemether-
Lumefantrine
Provider/hospital Recurrent Drugs 0.04 0.08 0.13 0.51 0.91
Staff salaries 3.98 3.98 3.98 3.98 3.98
Rental of building 0.17 0.17 0.17 0.17 0.17
Utilities 0.44 0.44 0.44 0.44 0.44
Consumables 0.13 0.13 0.13 0.13 0.13
Capital Microscope 0.33 0.33 0.33 0.33 0.33
Subtotal 5.09 5.13 5.18 5.56 5.96
Patient and family Direct Medication 0.14 0.14 0.14 0.14 0.14
Hospital fees 0.01 0.01 0.01 0.01 0.01
Transportation 1.35 1.35 1.35 1.35 1.35
Miscellaneous 0.26 0.26 0.26 0.26 0.26
Indirect Time spent at
Teule hospital
a
2.03 2.03 0.64 0.41 0.30
Time spent travelling
to Teule
b
0.15 0.15 0.05 0.03 0.02
Time spent caring for
sick child at home
c
11.70 11.70 3.68 2.39 1.75
Subtotal 15.64 15.64 6.13 4.59 3.83
Total 20.73 20.77 11.31 10.15 9.79
aThe mean time spent at Teule Hospital was 36 h.
bThe mean time spent travelling to hospital was 3 h.
cThe mean time spent away from normal activities at home while caring for a child with malaria was 8 d.
DOI: 10.1371/journal.pmed.0030373.t001
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This is, to our knowledge, the ﬁrst ﬁeld-based study to
compare the cost-effectiveness of the three available drug
combinations recommended by a consultative group of WHO
for deployment by countries when they move from mono-
therapy [2]. For each treatment, two sets of cost-effectiveness
ratios were presented. The ﬁrst set were gross estimates that
did not take into account potential resource savings; the
second set did (i.e., net cost-effectiveness ratios). Both sets of
ratios indicate that, whilst AL is the most expensive drug, in
this context of malaria that is highly resistant to both SP and
AQ, it is the most-cost-effective of the four malaria treat-
ments. Despite the drop in the effectiveness of all treatments
between days 14 and 28 due to a combination of reinfection
and recrudescence of malaria, savings at day 28 for AL are
one-third higher than the initial programme costs faced by
providers and patients.
This clear and striking ﬁnding has to be interpreted with
three notes of caution, all of which are important in trying to
generalise the messages of the study. Firstly, and obviously,
AL is the most cost-effective drug despite being the most
expensive because it is signiﬁcantly more effective than other
options and is therefore likely to reduce the need for further
treatment. This will not, however, necessarily be the case in
parts of Africa where recrudescence following SP and AQ
treatment (and their combination) is lower, so the relative
advantage of this ACT is smaller [19,20]. In particular, where
rates of AQ resistance are lower—which they are especially in
West Africa—both AQþAS and AQþSP will be relatively more
cost-effective, and where these combinations are as clinically
effective as AL in preventing recrudescence they will be more
cost-effective than AL.
Diagnostic accuracy has important operational implica-
tions. Our results show that accuracy of diagnosis plays an
important role in the estimation of effectiveness of combi-
nation therapy for malaria. If cost-effectiveness of ACTs is
undermined in this way then political support for them is
unlikely to be sustained. In this study, double-read research
microscopy was used to conﬁrm malaria and only those with a
positive result received treatment. In practice, however,
microscopes are not widely used in many parts of Africa
and clinical diagnosis tends to be the norm. Moreover, recent
studies in Tanzania and elsewhere provide evidence that, in
practice, many patients with a negative result go on to be
treated for malaria [21]. Drawing on local data demonstrating
that between 23% and 70% of all those with a negative test
will in fact, be given an antimalarial (H. Reyburn, personal
communication), we explored the impact on cost-effective-
ness of these misdiagnosis rates. If approximately 70% of
patients are wrongly diagnosed with malaria (and in low-
transmission settings the proportion can be even higher),
then the cost per case averted for AQþSP compared to AQ
rise three-fold. AL and AQþAS remain dominant over AQ
but the economic case for these treatments is weakened since
cases averted have fallen and cost savings remain the same.
Given the importance of accuracy of diagnosis, we have
disaggregated all cost and effects so that cost-effectiveness
ratios can be easily recalculated to take account of different
levels of diagnostic accuracy. Improving diagnostic accuracy
Table 2. Costs (US$), Effects, and Cost-Effectiveness
Measure Perspective Description Amodiaquine
(n ¼ 270)
a
Amodiaquine þ
Sulfadoxine-Pyrimethamine
(n ¼ 507)
a
Amodiaquine þ
Artesunate
(n ¼ 515)
a
Artemether-
Lumefantrine
(n ¼ 519)
a
Programme cost Provider Cost per patient 5.13 5.18 5.56 5.96
Household Cost per patient 15.64 6.13 4.59 3.83
Total 5,607.90 5,734.17 5,227.25 5,081.01
Clinical outcomes Cases averted at day 14 145 379 437 495
Cases averted by day 28 57 181 279 382
Gross cost-effectiveness Provider Cost per case averted at day 14 — 5.30 5.06 4.88
Cost per case averted at day 28 — 10.01 6.66 5.26
Societal Cost per case averted at day 14 — 0.53  1.30  1.51
Cost per case averted at day 28 — 1.02  1.71  1.62
Resource savings Provider
b Resource savings day 14 738.05 1,929.11 2,224.33 2,519.55
Resource savings day 28 290.13 921.29 1,420.11 1,944.38
Societal
c Resource savings day 14 3,005.85 7,856.67 9,059.01 10,261.35
Resource savings day 28 1,181.61 3,752.13 5,783.67 7,918.86
Net costs/savings
d Provider Day 14 647.05 697.15 639.07 573.69
Day 28 1,094.97 1,704.97 1,443.29 1,148.86
Societal Day 14 2,602.05  2,122.5  3,831.76  5,180.34
Day 28 4,426.29 1,982.04  556.42  2,837.85
Net cost-effectiveness Provider Cost per case averted at day 14 — 0.21  0.03  0.21
Cost per case averted at day 28 — 4.92 1.57 0.17
Societal Cost per case averted at day 14 —  20.19  22.03  22.24
Cost per case averted at day 28 —  19.71  22.44  22.35
an, number of patients in each category
bThis is based on the provider cost of current treatment per patient with SP (i.e., US$5.09). See Table 1.
cThis is based on the total cost of current treatment per patient with SP (i.e., US$20.73). See Table 1.
dNet costs or net savings are calculated by subtracting resource savings from programme costs.
DOI: 10.1371/journal.pmed.0030373.t002
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Cost-Effectiveness of ACTsbecomes a critical issue if ACTs are to be made more cost-
effective and their deployment is to be sustainable.
While resource savings are a legitimate outcome of many
interventions they tend inevitably to be less precise than
estimates of programme costs. For example, adherence levels
may be higher under trial conditions. The data from this
study come from an effectiveness study conducted in a setting
similar to outpatient practice in children, with drugs taken
unsupervised at home, rather than efﬁcacy data from trials
where all doses are supervised, but families may have
perceived trial-based treatment to be of a higher quality
and this may promote adherence and, in turn, cases of
malaria averted. The lack of payment for ACTs in the trial
reﬂects the current policy in Tanzania. However, the inﬂux of
these drugs in the private sector may give families an
incentive to save or to sell extra drugs instead of taking the
correct dose [9]. These downward pressures on resource
savings will to some extent be countered by other factors such
as savings to patients and their families resulting from
spending less time travelling to hospital, waiting at hospital
for treatment, or caring for sick children at home.
In this study all cost and cost-effectiveness estimates are
shown from two perspectives: societal and provider. Depend-
ing on the perspective taken the results differ substantially.
For example, both the programme costs and the resource
savings to patients and their families are greater than those to
the health service. This translates into lower cost-effectiveness
ratios under a societal perspective than under a provider one.
When comparing these results with cost-effectiveness ratios
for other malaria control or health interventions it is
important to ensure that, as far as possible, like is being
compared with like and the starting point for this should be
the perspective of the evaluation. Again, we have shown
estimates based on both perspectives to allow readers to adopt
the one that most suits the context in which they are working.
Finally, it has been suggested that a cost-effectiveness ratio
less than double the annual income per capita might be an
acceptable threshold value for most governments deciding
which intervention to fund [22]. The ﬁndings from this study
fall well below the average annual per capita income of
US$120 for Tanzania [23]. ‘‘Thresholds,’’ however, are only a
guide to decision-makers. Medicines such as AL require
considerable upfront investment in order to realise any
beneﬁts, and in particular are likely to need investment in
improving diagnostic accuracy. It is difﬁcult to see how most
African governments can meet this challenge alone given that
they currently devote less than US$5 per person annually to
public health [24]. This study demonstrates that in areas of
Africa where monotherapy is failing badly, ACTs, despite
being more expensive than monotherapy, can be very cost-
effective provided that the drugs are prescribed only to those
with malaria. The external investment, which will be needed
to subsidise drugs even at current costs, and to improve
targeting to those with malaria, is clearly justiﬁed on the basis
of these data.
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Editors’ Summary
Background. For many years, malaria was treated with a course of a
single drug. This type of treatment made it easy for malaria parasites to
become resistant to antimalarial drugs. This is a major factor contributing
to the continuing high death rate from the disease. However, although
parasites can easily adapt to resist one drug, adapting to combinations
of two or three drugs is much harder. Scientists have therefore
developed combinations of antimalarial drugs. One component of these
combinations is artemisinin—derived from a Chinese shrub. However,
these combination therapies are much more expensive than the older
treatments.
The regions worst affected by malaria—Africa and Asia—are also
the poorest. And, in these areas, where both individual and government
resources are scarce, antimalarial treatments must be cost-effective as
well as clinically effective.
Why Was This Study Done? Most of the estimated 1 million to 3 million
people worldwide killed by malaria every year are young children in sub-
Saharan Africa. Growing drug resistance, poor prevention programs, and
a frequent inability of patients to pay for treatment mean that effective
therapy is desperately needed in this part of the world. However,
because of differences in drug resistance between regions, a drug
combination will not work everywhere. In addition, because of low
annual incomes (the average in Tanzania is US$120), heavy subsidies will
probably be required to ensure that combination treatments are widely
used. With several healthcare problems competing for resources,
policymakers are likely to subsidize only the most cost-effective
treatments. The researchers wanted to provide policymakers with
information on how different combinations of malaria drugs compare
in terms of costs, health effects, and cost-effectiveness, so that they can
decide which treatment is best for their region.
What Did the Researchers Do and Find? They compared three
combinations that the World Health Organization recommends for
countries when making the transition from single-drug therapy. The
three combinations—amodiaquine (AQ) and sulfadoxine-pyrimethamine
(SP); AQ and artesunate (AS); and artemether-lumefantrine (AL)—were
used to treat Tanzanian children. The researchers wanted to find out how
many cases of malaria each combination averted (which is also an
indication of how much money it saved) and how much the treatment
cost. They looked at costs and savings from the perspectives of both
healthcare providers and patients.
Compared with no treatment, AL proved to be the most cost-
effective; although it cost more for the provider (US$3.01 at day 28 of
treatment) than the others, its effectiveness in getting rid of the parasite
meant it would save the cost of future treatment. By day 28, AL had
averted 382 cases of malaria compared with 279 for AQþAS, 181 for
AQþSP, and 57 for AQ alone. Also, higher proportions of inaccurate
diagnoses of malaria led to lower cost-effectiveness of treatments.
What Do These Findings Mean? Despite being more expensive, newer
drugs can be cost-effective where alternatives fail. Although AL was the
most cost-effective in places (such as Tanzania) where the malaria
parasites are highly resistant to SP and AQ, the picture is likely to change
for other areas. In West Africa, for example, AQ resistance is lower, and
AQþSP and AQþAS would probably be more cost-effective. And in areas
where both these combinations are just as good as AL in preventing
recurring disease, they would be more cost-effective than AL. However,
since AQ and SP have been used singly for many years, the likelihood is
that resistance to these drugs will continue to increase. Accurate
diagnosis turns out to be very important for maintaining the cost-
effectiveness of combination antimalarial therapies. This will be essential
if they are to be incorporated as a sustainable part of local health
policies. The researchers also point out that, depending on which
perspective is taken (provider or patient), the cost-effectiveness of
treatments differs, making it important to compare like with like.
Although investing in costly AL treatments and improving
diagnostic capabilities will be a challenge for African governments that
currently spend less than US$5 per person per year on healthcare, it will
be necessary if they are to seriously tackle the malaria epidemic.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030373
  The US Centers for Disease Control and Prevention provides malaria
information aimed at the general public, physicians, and health
workers
  The Wellcome Trust; also has malaria information for the general
public and covers the science of malaria research, including a
downloadable animation of the parasite’s life cycle
  Medicines for Malaria Venture (MMV) is a charity created to develop
new antimalarial drugs through public-private partnerships
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